An interventional study of Standard of Care (SOC) and Pharmacist-led digital platform assisted care in Acute Myocardial Infarction (AMI), sponsored by National University Heart Centre, Singapore. Active, not recruiting at 6 sites in Singapore. Open to participants aged 21 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by National University Heart Centre, Singapore · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Myocardial Infarction with a site in Singapore — 2 open to participants now, 4 under way, 1 of them phase 3. Myocardial Infarction · Singapore.
Among the 16 studies in Myocardial Infarction with a site in Singapore, this one is the 5th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2023, is one of 6 with no phase, and was the 16th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →2 of the 16 studies in Myocardial Infarction with a site in Singapore are open now. Recruiting first, the newest first:
National Heart Centre Singapore · Sites in Singapore
Ages 21–60
Western Sydney Local Health District · Sites in Singapore, United States, Australia and 12 more countries
Ages 18–85
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 21 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 4
First in 2002; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,633 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 594 across the 14 interventional studies, 1,600 across the 2 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 16 have an industry lead sponsor. The 10 most frequent:
National University Heart Centre, Singapore is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
National University Heart Centre, Singapore has 1 study filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Myocardial Infarction with a site in Singapore, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Acute Myocardial Infarction - allied Health Oriented, Patient centered, and digitally Enabled care (AMI-HOPE) program is a model of care designed to improve post-AMI well-being, safety, and outcomes through greater involvement of AHPs in patient care and integrating digital technologies into routine primary care disease management. AMI-HOPE aims to deliver solutions to these identified gaps of care which will transform healthcare planning both at cluster and national levels. The cornerstone of the AMI-HOPE program will be upskilling pharmacists to take on low-intermediate complexity clinician roles during the post-discharge period. The first 6 months will be anchored by tertiary care before a handoff to primary care. This frees up cardiologists to focus on high complexity cases.
The AMI-HOPE program addresses three critical healthcare challenges: insufficient specialist capacity, limited outpatient clinic infrastructure, and excessive dependence on hospital-based rather than community-based care during the vulnerable early post-discharge period for myocardial infarction patients. The program trains pharmacists to provide comprehensive post-MI (Myocardial Infarction) care through personalized cardiovascular medication optimization, targeted interventions for patients with reduced ejection fraction, smoking cessation support, and lifestyle counseling covering diet and exercise. Care delivery occurs remotely through integrated digital health platforms that facilitate continuous vital signs monitoring, deliver structured patient education at strategic intervals, and promote effective self-management capabilities.
This proof-of-value stepped-wedge pragmatic trial that evaluates the effectiveness of the AMI-HOPE intervention is conducted across seven hospitals and eighteen primary care polyclinics spanning Singapore's three health clusters.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard of Care
Other: Standard of Care (SOC)
AMI-HOPE centers around a digital platform that offers continuous telemonitoring on patients' vitals, tailored medication prescription with support from pharmacists, and personalised lifestyle nudges and educational material.
Other: Pharmacist-led digital platform assisted care
Standard of care treatment without the pharmacist-led digital platform assisted care
Up titration of medications by pharmacist. AMI-HOPE centers around a digital platform that offers continuous telemonitoring on patients' vitals, tailored medication prescription with support from pharmacists and personalised lifestyle nudges and educational material.
Death and Unplanned Cardiovascular Disease (CVD) related (non-fatal MI, non-fatal stroke, others) rehospitalizations
Counts and time to any events of death or unplanned CVD related rehospitalizations
Time frame: between enrolment and end of 12-month follow up
Absolute change in concentration of Low-Density Lipoprotein Cholesterol (LDL-C)
Absolute change in LDL-C (in mmol/L) from enrollment to end of 12 month follow up period
Time frame: between enrolment and end of 12-month follow up
Change in Blood Pressure (BP)
Absolute change in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) (in mmHg) from enrollment to end of 12 month follow up period
Time frame: At discharge, 2 week, 1, 3, 6, 9 &12 months
Change in Haemoglobin A1c (HbA1c)
Absolute change in HbA1c (in %) from enrollment to end of 12 month follow up period
Time frame: between enrolment and end of 12-month follow up
EuroQoL (Quality of Life)-5 Dimensions (EQ-5D) Scores in Participants
EQ-5D was calculated to evaluate quality of life (QoL) in participants. EQ-5D is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.
Time frame: At 1 month and 12 month
Patient Activation Measure (PAM-13) Scores in Participants
The Patient Activation Measure 13 (PAM-13) is a non-disease-specific survey that assesses a patient's knowledge, skills, and confidence for self-management. It uses 13 items on a 4-point Likert scale, with the raw sum score (ranging from 13-52) being transformed into a standardized 0-100 metric.
Time frame: At discharge and 6month
Seattle Angina Questionnaire-7 (SAQ-7) Scores in Participants
The change from baseline in Health-Related Quality of Life (HRQOL) is assessed by the SAQ-7. The SAQ-7 is a validated tool assessing three domains: physical limitation, angina frequency, and quality of life. An overall summary score is calculated by averaging the three domain scores (0-100), where higher scores indicate better health status (i.e., less frequent angina, better function, and higher quality of life).
Time frame: At 1 month and 12 month
Patient Health Questionnaire-9 (PHQ-9) Scores in Participants
The PHQ-9 is a validated 9-item self-report instrument used for screening and assessing the severity of depression. Each item is scored from 0 ("not at all") to 3 ("nearly every day") based on symptom frequency over the past two weeks, yielding a total score from 0 to 27, with higher scores indicating greater depression severity.
Time frame: At 1month and 12 month
Presence of angina pectoris as determined by the Rose Angina Questionnaire
The Rose Angina Questionnaire is a standardized, validated set of questions used to identify the presence of angina pectoris in epidemiological studies. It consists of a structured interview algorithm that classifies participants based on their responses to questions about chest pain characteristics, leading to a categorical outcome (e.g., definite angina, possible angina, or no angina).
Time frame: At 1month and 12month
Dose of ACE/ARB/MRA inhibitor
Change in drug intensity score for ACE inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (ACE I/ARB/ARNI) and beta blockers, to assess the effect of the pharmacist led intervention on prescription, early up titration, and adherence to drugs, and the subsequent impact on LDL C, blood pressure, HbA1c control, and left ventricular ejection fraction (LVEF).
Time frame: At discharge, 1, 3, 6 &12 months
Percentage of patients smoking
Each patient would be asked to indicate whether they are currently an active smoker(yes/no) at each point of assessment (at 1,3, 6 \& 12 month). The change in percentage of active smoker in the duration of the programme is use to assess the effectiveness of the smoking cessation programme.
Time frame: At 1,3, 6 & 12 month
Length of stay
To assess the clinical efficiency of the intervention
Time frame: Baseline
Cost-effectiveness
Health benefits expressed in Quality-Adjusted Life Years (QALYs) and incremental cost-effectiveness ratio (ICER) as the incremental cost of intervention delivery divided by the incremental health outcome (QALYs gained), to assess cost-effectiveness
Time frame: At the end of 12-month follow up
Started Jan 2023 (actual). Primary completion is estimated for Sep 2026, 44 months after the start.
Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 44 months is above that.
Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National University Heart Centre, Singapore